Therapeutic Potential of Berberine in Mitigating Liver Injury Induced by Valproic Acid in Wistar Rats

To assess the therapeutic potential of berberine in mitigating liver injury induced by valproic acid (VPA). The study also focuses on understanding oxidative stress pathways and their histopathological effects. Methods: This research focused on the hepatoprotective effects of berberine against valproic acid (VPA)-induced hepatotoxicity in rats. Comprehensive assessments of body weight, liver function, oxidative stress markers, and histopathology provided significant insights into the protective effects of these compounds. Result: VPA caused marked toxicity, including weight loss, liver enlargement, elevated liver markers, and oxidative stress, indicating severe hepatic injury. Berberine and silymarin treatment reversed these effects, with berberine II showing superior efficacy. Berberine restored body and liver weight, reduced ALT, AST, ALP, GGT, and bilirubin levels, and improved protein synthesis. It also enhanced antioxidant defences by increasing CAT, SOD, GSH, and GPx while reducing MDA levels. Histological analysis confirmed reduced inflammation and tissue damage. Berberine showed strong hepatoprotective and antioxidant effects against VPA-induced liver injury, supporting its therapeutic potential. discussion: Overall, berberine demonstrated strong hepatoprotective and antioxidant effects against VPA-induced liver injury, supporting its therapeutic potential in managing drug-induced hepatotoxicity. Discussion: Significant hepatotoxicity was brought on by valproic acid (VPA), as seen by increased liver enzymes, oxidative stress, and histological damage. By improving antioxidant defences, lowering lipid peroxidation, and restoring liver function, berberine therapy dramatically reversed these consequences. Histological improvements further validated its hepatoprotective activity. Berberine's effectiveness provides a potential substitute or supplemental treatment for the future. Although research shows promise as a treatment, human safety and efficacy must be confirmed through clinical trials. Conclusion: The results conclude the potential therapeutic application of berberine as a hepatoprotective agent, particularly in cases of drug-induced liver injury. The similar efficacy of berberine and silymarin suggests that berberine may serve as an alternative or adjunct hepatoprotective treatment. To assess its safety and effectiveness in human beings, more clinical research is necessary.